{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:32:45Z","timestamp":1776720765686,"version":"3.51.2"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.antiviral.2013.03.003","type":"journal-article","created":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T00:20:58Z","timestamp":1363220458000},"page":"186-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds"],"prefix":"10.1016","volume":"98","author":[{"given":"Eric","family":"Rhoden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shur-wern","family":"Wang-Chern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Steven","family":"Oberste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2013.03.003_b0005","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1128\/AAC.41.6.1220","article-title":"SCH 48,973: a potent, broad-spectrum, antienterovirus compound","volume":"41","author":"Buontempo","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.003_b0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.antiviral.2008.04.002","article-title":"A case for developing antiviral drugs against polio","volume":"79","author":"Collett","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.03.003_b0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3201\/eid1404.070439","article-title":"Potential use of antiviral agents in polio eradication","volume":"14","author":"De Palma","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2013.03.003_b0020","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/med.20125","article-title":"Selective inhibitors of picornavirus replication","volume":"28","author":"De Palma","year":"2008","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.antiviral.2013.03.003_b0025","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1021\/jm030166l","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics","volume":"46","author":"Dragovich","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2013.03.003_b0030","doi-asserted-by":"crossref","unstructured":"Duintjer Tebbens, R.J., Pallansch, M.A., Chumakov, K.M., Halsey, N.A., Hovi, T., Minor, P.D., Modlin, J.F., Patriarca, P.A., Sutter, R.W., Wright, P.F., Wassilak, S.G.F., Cochi, S.L., Kim, J.-H., Thompson, K.M., in press. Expert review on poliovirus immunity and transmission. Risk Anal. http:\/\/dx.doi.org\/10.1111\/risa.12022.","DOI":"10.1111\/risa.12022"},{"key":"10.1016\/j.antiviral.2013.03.003_b0035","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1126\/science.2994218","article-title":"Three-dimensional structure of poliovirus at 2.9 A resolution","volume":"229","author":"Hogle","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2013.03.003_b0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0166-3542(00)00106-6","article-title":"In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses","volume":"47","author":"Kaiser","year":"2000","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.03.003_b0045","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1128\/AAC.00539-12","article-title":"Characterization of poliovirus variants selected for resistance to the antiviral compound V-073","volume":"56","author":"Liu","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.003_b0050","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.mi.46.100192.003223","article-title":"Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment","volume":"46","author":"McKinlay","year":"1992","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2013.03.003_b0055","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","article-title":"Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2013.03.003_b0060","series-title":"Exploring the Role of Antiviral Drugs in the Eradication of Polio","author":"National Research Council","year":"2006"},{"key":"10.1016\/j.antiviral.2013.03.003_b0065","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/AAC.00671-09","article-title":"In vitro antiviral activity of V-073 against polioviruses","volume":"53","author":"Oberste","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.003_b0070","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.antiviral.2006.03.011","article-title":"Rhinovirus chemotherapy","volume":"71","author":"Patick","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.03.003_b0075","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1128\/AAC.43.10.2444","article-title":"In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease","volume":"43","author":"Patick","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.003_b0080","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.49.6.2267-2275.2005","article-title":"In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease","volume":"49","author":"Patick","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.003_b0085","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1128\/JVI.63.5.2002-2007.1989","article-title":"Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors","volume":"63","author":"Pevear","year":"1989","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2013.03.003_b0090","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.43.9.2109","article-title":"Activity of pleconaril against enteroviruses","volume":"43","author":"Pevear","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2013.03.003_b0095","series-title":"MacSynergy II User\u2019s Manual","author":"Prichard","year":"1993"},{"key":"10.1016\/j.antiviral.2013.03.003_b0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug\u2013drug interactions","volume":"14","author":"Prichard","year":"1990","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.03.003_b0105","series-title":"Vaccines Saunders","article-title":"Poliovirus vaccine-live","author":"Sutter","year":"2008"},{"key":"10.1016\/j.antiviral.2013.03.003_b0110","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.antiviral.2011.03.187","article-title":"Towards the design of combination therapy for the treatment of enterovirus infections","volume":"90","author":"Thibaut","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2013.03.003_b0115","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1021\/jm0202876","article-title":"An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus","volume":"46","author":"Watson","year":"2003","journal-title":"J. Med. Chem."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354213000570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T21:41:55Z","timestamp":1595540515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354213000570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0166354213000570"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.03.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2013.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}